Litcius/Paper detail

Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma

Chunmeng Zhang, Pranita Atri, Palanisamy Nallasamy, Seema Parte, Sanchita Rauth, Rama Krishna Nimmakayala, Saravanakumar Marimuthu, Ramakanth Chirravuri‐Venkata, Rakesh Bhatia, Sushanta Halder, Ashu Shah, Jesse L. Cox, Lynette M. Smith, Sushil Kumar, Jason M. Foster, Rakesh C. Kukreja, Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Surinder K. Batra

2022Cancer Letters17 citationsDOIOpen Access PDF

Topics & Concepts

MucinCancer researchPancreatic cancerBosutinibGemcitabineErlotinibMesothelinBiologyChemistryCancerPharmacologyBiochemistryDasatinibMyeloid leukemiaGeneticsImatinibEpidermal growth factor receptorPancreatic and Hepatic Oncology ResearchGlycosylation and Glycoproteins ResearchNeuroendocrine Tumor Research Advances
Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma | Litcius